康复新液联合奥美拉唑治疗Ⅱ～Ⅲ级反流性食管炎效果研究
|
摘要
目的:探讨奥美拉唑与康复新液联合治疗Ⅱ～Ⅲ级反流性食管炎的效果。方法:选择Ⅱ～Ⅲ级反流性食管炎患者122例,以随机数表法将其分为对照组与研究组,每组各61例。对照组口服奥美拉唑治疗,研究组在此基础上口服康复新液治疗。根据2002年试行的《中药新药临床研究指导原则》对比两组临床疗效,根据Savary-Miller标准对比两组内镜下疗效,对比两组治疗期间的不良反应,以及停药4周后的复发情况。结果:研究组治疗的总有效率为91.80%高于对照组77.05%(P<0.05)。研究组内镜观察下的总有效率为88.52%高于对照组73.77%(P<0.05)。两组不良反应发生率对比差异无统计学意义(P>0.05)。停药4周后随访显示,研究组的复发率13.11%低于对照组29.51%(P<0.05)。结论:奥美拉唑与康复新液联合治疗Ⅱ～Ⅲ级反流性食管炎效果显著,且降低了复发率,适于临床应用。
Objective:To explore the effect of omeprazole combined with Kangfuxin liquid in the treatment of reflux esophagitis of gradeⅡto gradeⅢ.Methods:122 patients with grade Ⅱ～Ⅲ reflux esophagitis were divided into a control group and a study group with 61 cases in each group.The control group was treated with omeprazole,and the study group was treated with Kangfuxin liquid.According to the clinical study guiding principles of Chinese medicine new medicine in 2002,the clinical efficacy of the two groups was compared.According to the Savary-Miller standard,the efficacy of the two groups was compared,the adverse reactions during the treatment of the two groups were compared,and the recurrence of the two groups after the withdrawal of 4 W was compared.Results:The total effective rate of the study group was 91.80%,which was higher than that of the control group(77.05%)(P<0.05).The total effective rate of the study group under endoscopy was 88.52%,which was higher than that of the control group 73.77%(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After the withdrawal of 4 W,the recurrence rate in the study group was 13.11%lower than that in the control group 29.51%(P<0.05).Conclusion:Omeprazole combined with Kangfuxin Liquid is effective in treating gradeⅡ ～ Ⅲ grade reflux esophagitis,and significantly reduces the relapse rate.
Objective:To explore the effect of omeprazole combined with Kangfuxin liquid in the treatment of reflux esophagitis of gradeⅡto gradeⅢ.Methods:122 patients with grade Ⅱ～Ⅲ reflux esophagitis were divided into a control group and a study group with 61 cases in each group.The control group was treated with omeprazole,and the study group was treated with Kangfuxin liquid.According to the clinical study guiding principles of Chinese medicine new medicine in 2002,the clinical efficacy of the two groups was compared.According to the Savary-Miller standard,the efficacy of the two groups was compared,the adverse reactions during the treatment of the two groups were compared,and the recurrence of the two groups after the withdrawal of 4 W was compared.Results:The total effective rate of the study group was 91.80%,which was higher than that of the control group(77.05%)(P<0.05).The total effective rate of the study group under endoscopy was 88.52%,which was higher than that of the control group 73.77%(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After the withdrawal of 4 W,the recurrence rate in the study group was 13.11%lower than that in the control group 29.51%(P<0.05).Conclusion:Omeprazole combined with Kangfuxin Liquid is effective in treating gradeⅡ ～ Ⅲ grade reflux esophagitis,and significantly reduces the relapse rate.
引文
[1]李吉梅.埃索美拉唑治疗反流性食管炎75例临床观察[J].陕西医学杂志,2017,46(9):1286-1288.
[2]刘争辉,张成明,刘力.泮托拉唑肠溶胶囊联合多潘立酮混悬液、达喜治疗反流性食管炎临床观察[J].陕西医学杂志,2016,45(10):1436.
[3]Gadel-HN,Elhemaly Mohamed,HE,Bile reflux measurement and its contribution to the severity of reflux exophagitis[J].Saud J Gastroenterol,2017,13(4):15-17.
[4]赵瞻元,关俭.加减柴胡疏肝散联合奥美拉唑治疗肝胃不和型反流性食管炎的临床观察[J].中医临床研究,2018,10(4):67-69.
[5]王娟,单桂芹,曹嘉伽,等.康复新液联合铝镁加混悬液治疗放射性食管炎的疗效分析[J].现代肿瘤医学,2018,26(5):699-702.
[6]朱佳杰,李依洁,刘珊,等.中医外治法治疗胃食管反流病的Meta分析[J].世界中西医结合杂志,2017,12(12):1629-1636,1645.
[7]Katarzyna S,Janusz S,Maciej K.The prevalence of duodeno gastroesophageal reflux(DGER)in children and adolescents with esophagitis[J].Pol Gastroenterol,2015,16(3):12-15.
[8]王莉,牛春燕,徐锐,等.埃索美拉唑联合莫沙必利治疗反流性食管炎疗效和安全性Meta分析[J].解放军药学学报,2017,33(6):577-580.
[9]Zheng RN.Comparative study of omeprazole,lansoprezole,pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis[J].World J Gastroenterol,2015,15(8):33-35.
[10]张锐,刘静,周绍兵.痰热清注射液联合康复新液防治同期放化疗食管癌患者放射性食管炎的临床研究[J].现代中医药,2017,37(6):69-71.
[11]马玉涛,翟真真,周连泉,等.舒丽启能联合康复新液和达立通治疗老年人反流性食管炎的疗效评价[J].慢性病学杂志,2016,17(6):626-629.
[12]龙云,杨莉,张朝瑞,等.枳术宽中胶囊联合奥美拉唑钠肠溶片治疗老年胃食管反流病的疗效及对食管24小时pH值、生活质量的影响[J].陕西中医,2016,37(4):436-437.
[13]庞鹏宇,王沁易.曾升海教授从肝论治胃食管反流病经验[J].陕西中医,2016,37(3):344-345.
[14]李凤玉.雷贝拉唑、奥美拉唑治疗老年性反流性食管炎的临床效果分析[J].中国现代医生,2018,56(11):108-110.
[15]丁平军,罗曦.康复新液联合埃索美拉唑与莫沙必利治疗反流性食管炎38例[J].中国药业,2015,24(24):221-222.
[2]刘争辉,张成明,刘力.泮托拉唑肠溶胶囊联合多潘立酮混悬液、达喜治疗反流性食管炎临床观察[J].陕西医学杂志,2016,45(10):1436.
[3]Gadel-HN,Elhemaly Mohamed,HE,Bile reflux measurement and its contribution to the severity of reflux exophagitis[J].Saud J Gastroenterol,2017,13(4):15-17.
[4]赵瞻元,关俭.加减柴胡疏肝散联合奥美拉唑治疗肝胃不和型反流性食管炎的临床观察[J].中医临床研究,2018,10(4):67-69.
[5]王娟,单桂芹,曹嘉伽,等.康复新液联合铝镁加混悬液治疗放射性食管炎的疗效分析[J].现代肿瘤医学,2018,26(5):699-702.
[6]朱佳杰,李依洁,刘珊,等.中医外治法治疗胃食管反流病的Meta分析[J].世界中西医结合杂志,2017,12(12):1629-1636,1645.
[7]Katarzyna S,Janusz S,Maciej K.The prevalence of duodeno gastroesophageal reflux(DGER)in children and adolescents with esophagitis[J].Pol Gastroenterol,2015,16(3):12-15.
[8]王莉,牛春燕,徐锐,等.埃索美拉唑联合莫沙必利治疗反流性食管炎疗效和安全性Meta分析[J].解放军药学学报,2017,33(6):577-580.
[9]Zheng RN.Comparative study of omeprazole,lansoprezole,pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis[J].World J Gastroenterol,2015,15(8):33-35.
[10]张锐,刘静,周绍兵.痰热清注射液联合康复新液防治同期放化疗食管癌患者放射性食管炎的临床研究[J].现代中医药,2017,37(6):69-71.
[11]马玉涛,翟真真,周连泉,等.舒丽启能联合康复新液和达立通治疗老年人反流性食管炎的疗效评价[J].慢性病学杂志,2016,17(6):626-629.
[12]龙云,杨莉,张朝瑞,等.枳术宽中胶囊联合奥美拉唑钠肠溶片治疗老年胃食管反流病的疗效及对食管24小时pH值、生活质量的影响[J].陕西中医,2016,37(4):436-437.
[13]庞鹏宇,王沁易.曾升海教授从肝论治胃食管反流病经验[J].陕西中医,2016,37(3):344-345.
[14]李凤玉.雷贝拉唑、奥美拉唑治疗老年性反流性食管炎的临床效果分析[J].中国现代医生,2018,56(11):108-110.
[15]丁平军,罗曦.康复新液联合埃索美拉唑与莫沙必利治疗反流性食管炎38例[J].中国药业,2015,24(24):221-222.